Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:15 PM
Ignite Modification Date:
2025-12-24 @ 2:15 PM
NCT ID:
NCT05184595
Eligibility Criteria:
Inclusion Criteria:
* Age \> 18 years
* relapsed multiple myeloma, at least one prior line of treatment
* treatment with carfilzomib validated in a multidisciplinary consultation meeting and accepted by the patient
* The patient accepts mixed management and benefits from the support of his/her family and friends (see ANAES 2003 criteria). If the patient does not have a caregiver, he/she can still participate in the research and the absence of a caregiver will be collected.
* Patient capable of adhering to care (cf. ANAES 2003 criteria)
* Patient affiliated to a social security system or beneficiary of such a system.
* Patient having received full information on the organization of the research and having signed his or her informed consent
Exclusion Criteria:
* Person with a contraindication to carfilzomib
* Women of childbearing age who do not have effective contraception
* Persons referred to in articles L. 1121-5, L. 1121-7; L1121-8 and L1122-1-2 of the Public Health Code
* Pregnant woman, parturient or nursing mother
* Minor (not emancipated)
* Adult person under a legal protection measure (guardianship, curatorship, safeguard of justice)
* A person of full age who is unable to express his or her consent
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT05184595
Study Brief:
Protocol Section:
NCT05184595